

Review Article: Systematic Review, Meta-Analysis, Integrative Review, Scoping Review

THE EFFECT OF FLAVONOIDS IN PLANTS AS ANTIHYPERURICEMIA: A LITERATURE REVIEW

Diah Pitaloka Putri^{1*}, Kusuma Wijaya Ridi Putra²

¹Bachelor's Degree Study Program in Nutrition, College of Health Science of Husada Jombang

²Bachelor's Degree Study Program in Nursing Science, College of Health Science of Husada Jombang

***Correspondence:**

Diah Pitaloka Putri

Bachelor's Degree Study Program in Nutrition, College of Health Science of Husada Jombang

Veteran Road, Mancarmalang, Mancar, Peterongan, Jombang Regency, East Java Province, Indonesia - 61481

Email: diahpitalokaputri8@gmail.com

Article Info:

Received: February, 24th, 2024

Revised: June, 6th, 2024

Accepted: June, 7th, 2024

DOI:

<https://doi.org/10.36720/nhjk.v13i1.635>

Abstract

Background: Hyperuricemia is a condition on the level of uric acid in the blood increases, it is more than 6.0 mg/dL in women and more than 7.0 mg/dL in men and is currently a public health problem because of its increasing prevalence. Hyperuricemia is believed to have contributed to an increased risk of mortality and morbidity associated with various diseases such as metabolic syndrome, kidney disease, cardiovascular disease, etc. Flavonoids in plants can be used to help treat hyperuricemia due to it is believed to have low side effects.

Objective: The aim of this article was to review the effect of flavonoids on plants as anti-hyperuricemia.

Design: The design used in preparing this manuscript is a literature review by reviewing articles on the impact of flavonoids as anti-hyperuricemia.

Data Sources: Sources of information were obtained from research articles from 2004-2023 which were accessed through PubMed, Scopus, Scindirect, SpringerLink, and Google Scholar.

Review Methods: In the process of selecting articles to ensure the quality of the articles used in preparing this article, the authors used the PRISMA method. In addition, to avoid biased research results, the researchers carried out tests using the Joanna Briggs Institute (JBI) checklist. The authors independently reviewed study abstracts obtained through searches of five databases. In carrying out data extraction, the author held discussions to find out the results of the extraction.

Results: In this article, 15 in vivo studies related to the effect of plants containing flavonoids (kaemferol, luteolin, apigenin, rutin quercetin, morin, butein, vitexin, etc.) on reducing uric acid levels by various mechanisms from previous studies. The 15 articles used in preparing this literature review have met the requirements for use and avoided biased research results.

Conclusion: Based on several studies reported that flavonoids have an effect on lowering uric acid levels by inhibiting xanthine oxidase (XO) activity, affecting the expression of uric acid transporters in the kidneys which contribute to the increase of excretion of uric acid in urine.

Keywords: *Flavonoids, Anti-Hyperuricemia, Uric Acid, Kidneys*

INTRODUCTION

Hyperuricemia is a condition where there is an increase of uric acid levels in the blood. Uric acid is the end product of purine

metabolism in the body (Gustafsson & Unwin, 2013). Uric acid levels are classified as normal if they range from 2.6 mg/dL to 5.7 mg/dL in women and 3.5 mg/dL to 7 mg/dL in men

(Chen et al., 2016). Currently, hyperuricemia is a public health problem because the prevalence of hyperuricemia has continued to increase over the last 40 years (Edwards, 2009) and has increased to 10% in the world population (Gulab, 2016). The prevalence of hyperuricemia in China is 21% of total population, Italia is 6,7-9,1% (from 2005-2009) and Australia is reaching 16.6% of total population (Hong Liu et al., 2014; Ting et al., 2016; Trifirò et al., 2013).

Hyperuricemia can be caused by decreased excretion of uric acid and increased production of uric acid in the body (Choi, H.K., Mount, DB., Reginato, 2005; Dong et al., 2017; Ichida et al., 2012). Besides, factors that contribute to increase the uric acid levels include modern lifestyles and Western diets (consumption of foods high in purines, alcohol, and foods high in sugar), socioeconomic factors, gender, Body Mass Index (BMI), obesity (which contribute to increased uric acid secretion) and hypertension (C. F. Kuo et al., 2015; Raja et al., 2019; Rho et al., 2011; Tsushima et al., 2013). Epidemiological studies have reported that hyperuricemia is proven to be a factor that can increase the risk of morbidity and mortality associated with several diseases, including hypertension, diabetes mellitus, dyslipidemia, kidney disease, cardiovascular disease and heart failure (Bardin & Richette, 2014; Dong et al., 2017; Gustafsson & Unwin, 2013; Qiu et al., 2013).

Currently, the use of plants containing flavonoids is widely used in the health sector, various studies related to flavonoids are being developed because flavonoids have many benefits and are often used as an alternative or complementary to treat various diseases. In addition to having many benefits, flavonoids are easy to find because of their abundance in plants and have relatively cheap prices (Robinson & Zhang, 2011). Flavonoids have naturally occurring compounds in plants that can be found in vegetables, fruits, and whole grains. Flavonoids contain secondary metabolites that have been shown to have properties of antioxidant, anti-inflammatory,

anti-allergic, anti-cancer, anti-diabetic and anti-hyperuricemic (Abu Bakar et al., 2018; Al-Ishaq et al., 2019; Ekalu, 2020; Maheswari et al., 2016).

The content of flavonoids in plants can be found in all parts, such as roots, stems, leaves, flowers or fruit. The types of flavonoids that are commonly found in plants include apigenin, luteolin, quercetin, genistein, and rutin where these flavonoids are classified into several sub-classes (Panche et al., 2016). Flavonoids have potential as an alternative treatment of hyperuricemia, because flavonoids are believed to reduce uric acid levels (Siciliano et al., 2004). Previous research has stated that flavonoids can inhibit the activity of the xanthine oxidase enzyme, which inhibit xanthine oxidase.

Another research also reported that administration of the flavonoid (quercetin) for 4 weeks at a dose of 500 mg/day to 22 male respondents who had hyperuricemia, showed a decrease in uric acid levels by 26 μ M (Y. Shi & Williamson, 2016), administration of the flavonoid luteolin can reduce xanthine oxidase activity so that can reduce uric acid levels (Yan et al., 2013) and administration of apigenin at a dose of 50 mg/200 g/BW and 100 mg/200 g/BW for 7 days can inhibit xanthine oxidase enzyme activity in normal and hyperuricemic rats (Huang et al., 2011).

Based on the statements above, the authors prepared this literature article with the aim of conducting a review regarding the effect of flavonoids in plants as anti-hyperuricemia.

METHODS

Design

This manuscript was prepared using a Literature Review design.

Search Methods

Sources of information used to search for literature or articles were obtained from PubMed, Scopus, Scindirect, SpringerLink, and Google Scholar. It searched for published articles from 2004 to 2023. Keywords for searching published articles included

“Flavonoids” OR “Luteolin” OR “Apigenin” OR “Quercetin” OR “Rutin” OR “Kaemferol” OR “Medicinal Plants” OR “Uric Acid” OR “Hyperuricemia” OR/ And “Xanthine Oxidase”.

Search Outcome

Based on data obtained from five literature search databases, there were 183 articles that matched the keywords set by the authors. After conducting an initial review through abstracts that were in accordance with

the objectives of preparing this literature review, 50 articles were obtained that were suitable and could be accessed in full text. After that, the authors carried out another review regarding the inclusion criteria in the form of articles used that were the results of in vivo research. From this selection, 15 articles were obtained which were used in preparing this literature review. The flow of the article selection process used in this literature review is presented in Figure 1 below.




Figure 1. Flow Diagram for Identifying Scientific Articles used in Preparing Literature Reviews

Quality Appraisal

The author is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) method in conducting Quality Appraisal assessments.

Apart from that, the authors also used The Joanna Briggs Institute (JBI) checklist in assessing the risk of bias of the articles used. After conducting a Quality Appraisal using the PRISMA Methods and JBI Checklist, all

articles used in preparing this literature review met the requirements and did not show bias in the research results.

Data Abstraction

The authors independently reviewed research abstracts obtained through searches of five databases. After obtaining the full texts of relevant articles, the authors carried out data extraction independently using standard data extraction templates. In carrying out the data extraction, the authors held discussions to determine the results of the extraction.

Data Analysis/ Synthesis

The research used in preparing this literature review was fifteen articles which were the results of in vivo research. The results of data analysis from the fifteen articles are presented in Table 1 below.

RESULTS

Based on the results of selecting articles used in this literature review, it was found that 15 scientific articles met all the criteria set by the authors of which 15 scientific articles are the results of in vivo research. An overview of the 15 scientific articles can be seen in **Table 1** below.

Table 1. *In Vivo* Study The Effect of Flavonoid on the Decrease of Uric Acid Level.

Source	Bioactive Compound	Dose	Results	Mechanism
<i>Toona Sinensis</i> (Yuk et al., 2018), Korea.	Rutin, isoquercetin, pentagalloyl glucose, quercetin, afzelin.	300 mg/kg.	Isolates of bioactive compounds from <i>Toona sinensis</i> can reduce uric acid levels in rats induced by hyperuricemia with potassium oxonate.	It inhibits xanthine oxidase (XO) activity. Inhibitory potency 96.4% (pentagalloyl glucose), isoquercetin (47.8%), rutin (42.9%), quercetin (38.9%) and afzelin (31.7%).
<i>Aster Glehni</i> (Park et al., 2018), Korea.	Quercetin.	50, 100 and 200 mg/kg for 7 days intervention.	It can decrease uric acid level in hyperuricemic rats by 0,50 mg/Dl (dose of 50), 3m53 mg/Dl (dose of 100), 3,00 mg/Dl (200) dose.	It inhibits the activity of xanthine oxidase.
<i>Perilla Frutescens</i> (Huo et al., 2015), China.	Apigenin.	500,1000 and 2000 mg/kg for seven days.	It can reduce uric acid level from 300,7 μ mol/L to be 193,7 7 μ mol/L (500 dose), 188,77 μ mol/L (1000 dose), and 1317 μ mol/L (2000 dose).	It inhibits the activity of xanthine oxidase.
<i>Urtica Hyperborean</i> (Han et al., 2020), China.	Flavonoid (no specific kind of flavonoid).	0,78 and 2,34 mg/kg for seven days.	It can decrease uric acid level.	It decreases XOD (xanthine oxidase dehydrogenase) activity and ADA (adenosine deaminase), reduces URAT1 expression and increases OAT1 (uric acid transporter).
<i>Gnaphalium Affine</i> (Lin et al., 2018), China.	Luteolin 4-O-glucoside.	20, 40, 100 mg/kg for seven days.	It can increase of renal excretion of uric acid in the kidney of hyperuricemia rats.	It has the effect of uricosuric (increases the excretion of uric acid through urine) in hyperuricemic rats by reducing the expression of the organic ion transporter (URAT1) in the liver and inhibits the activity of the xanthine oxidase enzyme.

<i>Petroselinum Crispum</i> (Haidari et al., 2011), Iran.	Quercetin and kaemferol.	5 mg/kg for 14 days.	It can reduce uric acid levels, increase antioxidant capacity and increase MDA in hyperuricemic rats.	It has hyperuricemia effect by inhibiting of xanthine oxidase and xanthine dehydrogenase (XDH) activity.
<i>Marantodes Pumilum</i> (Rahmi et al., 2020), Malaysia.	Myricetin, quercetin and kaemferol.	250mg/kg for 14 days.	It can reduce uric acid levels, (anti-hyperuricemia) and inhibit the inflammation of gout (anti-inflammatory) in the rat that has been induced.	It has hyperuricemic effect by inhibiting xanthine oxidase activity in the liver and uricosuric effect, while anti-inflammatory effect by inhibiting cytokines and PGE2 (prostaglandin E2).
<i>Ramulus Mori</i> (Y. W. Shi et al., 2012), China.	Morin, quercetin, butein, kaemferol.	10, 20 dan 40 mg/kg for 7 days.	It can reduce uric acid, BUN and creatinine levels in hyperuricemic rats.	It has a uricosuric effect by downregulating renal URAT1 and GLUT9 expression and renal mOAT1 expression contributing to increased uric acid excretion.
<i>Sonneratia Apetala</i> (I. T. Jang et al., 2014), Korea.	Vitexin dan isorhamnetin.	50, 100 dan 200 mg/kg for 7 weeks.	It can reduce levels of uric acid, BUN, d, creatinine and can regulate kidney uric acid transporter in rats that have been induced by potassium oxonate.	It inhibits XO activity in the liver, reduces the expression of URAT1 and URAT9 and increases OAT1 in the process of inhibiting uric acid production and increasing uric acid excretion in the kidneys.
<i>Lippia Nodiflora</i> (Cheng et al., 2015), Malaysia.	6-hydroxyluteolin, 6-hydroxyluteolin-7-O-glycoside, nodifloretin.	200 mg/kg for 10 days.	It can reduce uric acid levels in hyperuricemic rats.	It inhibits xanthine oxidase and xanthine dehydrogenase activity and increases uric acid excretion in the kidneys.
<i>Apium Graveoluolens</i> (Dolati et al., 2018), Iran.	Apiin dan apigenin.	250,500 and 1000 mg/kg.	It can reduce uric acid levels in hyperuricemic rats.	It inhibits of xanthine oxidase and xanthine dehydrogenase activity in the liver.
<i>Hibiscus Sabdariffa</i> L. (C. Y. Kuo et al., 2012), Taiwan.	Catechin.	1%,2% and 5% for 5 weeks.	It can reduce uric acid levels in hyperuricemia induced potassium oxonate.	It decreases uric acid levels by inhibiting xanthine oxidase activity and increasing uricase activity to increase uric acid excretion.
<i>Plumeria Rubra</i> (Mohamed Isa et al., 2018), Malaysia.	kaempferol-3-O-glucoside, kaempferol-3-rutinoside, kaempferol, quercetin 3-O- α -L-arabinopyranoside, quercetin.	50,100 and 200 mg/kg for 7 days.	It can reduce uric acid levels in hyperuricemic rats.	It inhibits the activity of xanthine oxidase.
<i>Tinospora Crispa</i> (Harwoko & Warsinah, 2020), Indonesia.	Rutin.	-	It can reduce uric acid levels in hyperuricemic rats induced by potassium oxonate.	It inhibits the activity of xanthine oxidase.
<i>Biota Orientalis</i> (Zhu et al., 2004), Iran.	Quercetin dan rutin.	50 mg/kg (quercetin), 100 mg/kg (rutine).	It can reduce uric acid levels in hyperuricemic rats induced by potassium oxonate.	It inhibits the activity of xanthine oxidase.

DISCUSSION

Hyperuricemia

Hyperuricemia is a condition in which uric acid levels exceed normal values. Normal uric acid levels in humans are 2.6-5.7 mg/dL for premenopausal women and 3.5-7.0 mg/dL for men and postmenopausal women (Desideri et al., 2014; Khanna, 2012; Zhu, Y., Pandya, B., Choi, 2011). Increased of uric acid level in the blood can be caused by excessive uric acid production, decreased uric acid excretory function in the kidneys or a combination of both (Merriman, 2015; Su et al., 2014). Decreased uric acid excretory function in the kidneys can be caused by acute or chronic kidney disease, acidosis (ketoacidosis, lactic acidosis), drugs/toxins (diuretics, niacin) and hyperthyroidism (Dong et al., 2017).

Uric acid is the final product of purine metabolism that forms biological particles such as DNA, RNA, ATP and GTP (Chen et al., 2016). Endogenous purine products are estimated to be around 500-600 mg/day, while exogenous purine intake from food is around 100-200 mg/day (Desideri et al., 2014). The biosynthesis of uric acid in the body is catalyzed by the enzyme xanthine oxidase (XO), which is also known as xanthine oxidoreductase (XOR). XO enzyme is an enzyme that converts hypoxanthine to xanthine and then converts xanthine to uric acid. If the enzyme activity is not inhibited, it can increase

uric acid levels in blood serum (Grabowski et al., 2010). In the body, the kidneys play a key role in maintaining the balance of uric acid metabolism. The kidneys excrete 70% of the uric acid produced daily and 30% are excreted through the digestive tract. If the body is in excess of purines and the excretion of uric acid in the kidneys decreases, it will lead to the hyperuricemia (**Figure 2**).

Meanwhile, the increase of production of uric acid can be caused by: 1). High-purine diet. The intake of foods and beverages containing purines will cause more purines to be metabolized and produce uric acid (Chen et al., 2016; Villegas et al., 2012); 2). Other studies have also reported that an increase in meat and seafood consumption, followed by an increase in uric acid level (Yu et al., 2008); 3). Alcohol consumption. The consumption of alcohol is related to the increase of lactic acid and ketones and cause dehydration and decrease uric acid excretion in the kidneys (M. Wang et al., 2013). 4). Fructose consumption. Previous studies reported that fructose consumption can increase uric acid levels through the degradation process of ATP (H. K. Choi & Curhan, 2008). In addition, fructose consumption can also increase the risk of insulin resistance and hyperinsulinemia which can cause a decrease in uric acid excretion (H. K. Choi et al., 2010).




Figure 2. Mechanism of Hyperuricemia (Skoczyńska et al., 2020)

Other factors that can increase the risk of hyperuricemia include: Gender and BMI. Gender also affects the occurrence of

hyperuricemia. The results of previous studies reported that men have a higher risk of hyperuricemia than women, this is because

women have the hormone estrogen. The hormone estrogen has a role in increasing the excretion of uric acid and preventing the appearance of arthritis in women (Hak et al., 2010; C. F. Kuo et al., 2015). BMI also has a risk of increasing the incidence of hyperuricemia. A cross-sectional study in Hong Kong, stated that BMI and waist-to-hip ratio were also closely related to hyperuricemia. There are 2 factors associated with BMI and obesity, including excessive uric acid production and low uric acid excretion (Tanaka et al., 2015; Honggang Wang et al., 2014). The previous studies in obese experimental animals showed an increase in XO enzyme activity in white adipose tissue. Adipose tissue is produced and secretes uric acid, which ultimately contributes to the increase of serum urate levels in obese rats (Tsushima et al., 2013).

Currently, hyperuricemia has been shown to be a co-morbidity of several diseases. Several studies have proven that hyperuricemia is a risk factor for hypertension, heart failure, ischemic heart, and stroke (Storhaug et al., 2013; Zalawadiya et al., 2015). A study showed that respondents with uric acid levels > 7 mg/dL (Male), will increase the risk of hypertension by up to 80% (Benn et al., 2018). Hyperuricemia can cause hypertension by blocking the production of Nitric Oxidative (NO). NO can induce vasodilation to increase bloodstream, blood vessels, reduce the proliferation of

vascular smooth muscle cells and modulate thrombosis thus playing an important role in protecting blood vessels (Förstermann et al., 2017).

The development of hypertension will also increase the risk of CAD (Coronary Artery Disease) in hyperuricemic patients (Baker et al., 2007; Wu et al., 2017). Hyperuricemia can contribute to lipid peroxidation and increase cholesterol oxidase which plays a role in the development of atherosclerosis and will be associated with the incidence of CAD (Coronary Artery (Gómez et al., 2014).

Another diseases which associated with hyperuricemia are kidney disease Ather diseases which associated with hyperuricemia are kidney disease, gout and metabolic syndrome disease (Abbasian et al., 2016; H. Choi et al., 2016; Shih et al., 2015; Hongsha Wang et al., 2018; H. Yuan et al., 2015). The mechanism of hyperuricemia in increasing kidney disease (CKD) is through increased oxidative stress caused by NADP (Nicotinamide Adenine Dinucleotide Phosphate) and xanthine oxidase (Bove et al., 2017; Li et al., 2016) and reduces the production and bioavailability of nitric oxide (NO) and induces endothelial dysfunction (Y. J. Choi et al., 2014). Uric acid can also increase the production of inflammation including IL-1, IL-6 and cause glomerular hypertrophy and renal tubular fibrosis (Huifang Liu et al., 2017; Romi et al., 2017).




Figure 3. Diseases caused by Hyperuricemia (Hongsha Wang et al., 2018)

Metabolic syndrome is characterized by five health disorders, including abdominal obesity, hypertension, hypertriglyceridemia, dyslipidemia and diabetes mellitus (Alberti et al., 2009; Grundy, 2007). Previous studies reported that men who have uric acid > 7 mg/dL will have a 1.6-fold risk of developing metabolic syndrome compared to men with low uric acid levels and women who have uric acid levels >4.6 mg/dL are at risk have metabolic syndrome 2 times compared to women with low uric acid levels (Sui et al., 2008).

The decrease of excretion of uric acid in the kidneys is the first mechanism in developing metabolic syndrome. The second mechanism is impaired endothelial function which can lead to decreased release of nitric oxide (NO) from endothelial cells (Khosla et al., 2005). Uric acid can reduce insulin resistance (IR) by suppressing NO bioavailability, whereas hyperinsulinemia contributes to hyperuricemia by decreasing uric acid secretion in the kidneys and increasing uric acid-producing substrates (Kodama et al., 2009). The third mechanism, involving inflammation and oxidative changes in adiposity induced by uric acid, results in the metabolic syndrome (Sautin et al., 2007). The IR caused by an increase in the uric acid level causes the accumulation of liver lipids which is the main cause in the development of NAFLD. NAFLD is not merely associated with the metabolic syndrome but also functions as a manifestation of liver disease, oxidative stress that is directly caused by high uric acid and inflammatory processes (**Figure 4**).

Flavonoids for Hyperuricemia

Flavonoids are natural compounds found in plants and flavonoids contain secondary metabolites that are antioxidants (Maheswari et al., 2016). Flavonoids are found in many fruits, vegetables, nuts, seeds, cocoa, roots, stems, flowers, tea, and red wine (Pérez-Cano & Castell, 2016). Flavonoids can be classified into various classes, including anthocyanins, chalcones, flavanones, flavones,

flavonols, and isoflavonoids (Tremblé & Šmejkal, 2016).




Figure 4. Mechanism Hyperuricemia for Metabolic Syndrome (H. Yuan et al., 2015).

Flavonoid is related to various health benefits, so flavonoid is often used in various nutraceutical, pharmaceutical, medicinal, and cosmetic (Panche et al., 2016; Romano et al., 2013). Flavonoid has antioxidant, anti-inflammatory, antimutagenic, and anticarcinogenic properties and has the capacity to modulate the function of cellular enzymes. Besides, flavonoid also has function as inhibitors for several enzymes, such as XO, COX (*cyclo-oxygenase*), *lipoxigenase* and *phosphoinositide 3-kinase* (Ekalu, 2020). Currently, 65-80% of people in developing countries use flavonoids contained in plants as a complement or alternative to treat disease (Robinson & Zhang, 2011). Flavonoids are widely used because they have lower side effects compared to chemical drugs.

Several studies have indicated that the flavonoids contribute to anti-hyperuricemia activity by reducing uric acid levels and inhibiting the activity of the xanthine oxidase enzyme (De Souza et al., 2012; M. G. Jang et al., 2019; Spanou et al., 2012). This is evidenced by previous studies that reported that flavonoid in *Pleoratus* extract, *Momdica charantia ostreatus* extract and extract Red guava (*Psidium guajajana* Linn.) in rats

induced to hyperuricemia has been shown to reduce uric acid levels through inhibition of xanthine oxidase activity (Alsultane et al., 2014; I. Jang et al., 2014). Other studies reported that administration of *T. crista* stem extract at a dose of 100 mg/kg was able to reduce uric acid levels in hyperuricemia rats induced by potassium oxonate. This is influenced by the high content of flavonoids (31.08%) in the stem extract of *Tinospora crista* which has the potential as a uricostatic in the treatment of gout (Harwoko & Warsinah, 2020). Secondary mechanism of flavonoid to anti-hyperuricemia that have high inhibitory in reducing the activity of the xanthine oxidase enzyme. Plants that have low flavonoid content may not be able to optimally reduce xanthine oxidase inhibition 50. The presence of methylation of hydroxyl and hydroxylation groups at positions C5 and C7, as well as glycosylation and hydrogenation of C2=C3 in

ring B contained in flavonoids are believed to inhibit enzyme affinity. xanthine oxidase (M. Yuan et al., 2019) In addition, the presence of a C2=C3 double bond in conjugation with a 4-keto group in the C-ring, an ortho-dihydroxy (catechol) group in the B-ring and a hydroxyl group at position 5 have an important role in the single electron transfer mechanism, so that flavonoids can play a role. in inhibiting XO activity. The results of previous studies also reported that the basic chemical structure of the flavonol group with C2 and C3 double bonds was found to be very influential in the inhibition of high xanthine oxidase activity (Van Hoorn et al., 2002). Other studies reported that the hydroxyl groups C2, C5 and C7 in flavonoids (quercetin) had the effect of suppressing uric acid production by inhibiting xanthine oxidase activity in AML12 (alpha mouse liver 12) (Adachi et al., 2019).




Figure 5. Class of Flavonoids (Panche et al., 2016)

Another mechanism of flavonoids can decrease of uric acid by increasing the excretion of uric acid in the kidneys (S. Wang et al., 2019). This is evidenced by several previous studies reporting that flavonoid (chrysin/(5,7-dihydroxyl) has anti-hyperuricemic effect, regulates the expression of URAT1, GLUT9, OAT1 and ABCG2 in increasing uric acid excretion and has anti-inflammatory effect in

hyperuricemic rats by increasing IL concentration. -1β and reduce oxidative stress The administration of mangiferin from the leaf isolate of *Mangifera indica* L. can increase uric acid excretion and inhibit uric acid reabsorption by inhibiting the regulation of transporter expression in the kidney (reducing the expression of URAT1, GLUT9 and OAT10) (I. Jang et al., 2014), *Tinospora cardifolia* stem

extract can reduce uric acid levels through its uricosuric effect by inhibiting the expression of the uric acid transporter (Shah & Shah, 2015) and other studies reported that bioactive

compounds (flavonoids) play a role in regulating the expression of the uric acid transporter (Jiang et al., 2020) (Figure 6).




Figure 6. Effect of bioactive compounds on uric acid transporters in the kidney (Jiang et al., 2020)

CONCLUSION

Based on several studies reported that flavonoids have an effect on lowering uric acid levels by inhibiting xanthine oxidase (XO) activity, affecting the expression of uric acid transporters in the kidneys which contribute to the increase of excretion of uric acid in urine. Based on the results of the review that has been carried out, further research is needed to produce a nutraceutical product to help treat hyperisemia.

ACKNOWLEDGMENT

The authors would like to thank the College of Health Science of Husada Jombang for its support in preparing this manuscript.

DECLARATION OF CONFLICTING INTEREST

The authors declare that they have no conflict of interest in the preparation of this manuscript.

FUNDING

The preparation of this manuscript was funded by the authors themselves.

AUTHOR CONTRIBUTION

Diah Pitaloka Putri: Contribution in design, perform collecting article and analyze the literature.

Kusuma Wijaya Ridi Putra: Contribution for discussed the results and contributed to the final manuscript.

ORCID

Diah Pitaloka Putri

<https://orcid.org/0000-0002-4053-6200>

Kusuma Wijaya Ridi Putra

<https://orcid.org/0000-0003-2009-0392>

REFERENCES

- Abbasian, M., Ebrahimi, H., Delvarianzadeh, M., Norouzi, P., & fazli, mozhgan. (2016). Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahrood University of Medical Sciences. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 10(3), 132–136. <https://doi.org/10.1016/j.dsx.2016.01.003>
- Abu Bakar, F., Abu Bakar, M. F., Rahmat, A., Abdullah, N., Sabran, S. F., & Endrini, S. (2018). Anti-gout potential of Malaysian medicinal plants. *Frontiers in*

- Pharmacology*, 9(MAR).
<https://doi.org/10.3389/fphar.2018.00261>
- Adachi, S. ichi, Kondo, S., Sato, Y., Yoshizawa, F., & Yagasaki, K. (2019). Anti-hyperuricemic effect of isorhamnetin in cultured hepatocytes and model mice: structure–activity relationships of methylquercetins as inhibitors of uric acid production. *Cytotechnology*, 71(1), 181–192. <https://doi.org/10.1007/s10616-018-0275-8>
- Al-Ishaq, R. K., Abotaleb, M., Kubatka, P., Kajo, K., & Büsselberg, D. (2019). Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels. *Biomolecules*, 9(9). <https://doi.org/10.3390/biom9090430>
- Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J. C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International . *Circulation*, 120(16), 1640–1645. <https://doi.org/10.1161/CIRCULATION.AHA.109.192644>
- Alsultane, I., Ewadh, M., & Mohammed, M. (2014). Novel Natural Anti Gout Medication Extract from Momdica charantia. *Journal of Natural Science Research*, 4(17), 16–24.
- Baker, J. F., Schumacher, H. R., & Krishnan, E. (2007). Serum uric acid level and risk for peripheral arterial disease: Analysis of data from the multiple risk factor intervention trial. *Angiology*, 58(4), 450–457. <https://doi.org/10.1177/0003319707303444>
- Bardin, T., & Richette, P. (2014). Definition of hyperuricemia and gouty conditions. *Current Opinion in Rheumatology*, 26(2), 186–191. <https://doi.org/10.1097/BOR.0000000000000028>
- Benn, C. L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Ian Storer, R., & Vangjeli, C. (2018). Physiology of hyperuricemia and urate-lowering treatments. *Frontiers in Medicine*, 5(MAY), 1–28. <https://doi.org/10.3389/fmed.2018.00160>
- Bove, M., Cicero, A. F. G., & Borghi, C. (2017). The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. *Current Hypertension Reports*, 19(12). <https://doi.org/10.1007/s11906-017-0793-3>
- Chen, C. J., Lü, J. M., & Yao, Q. (2016). Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: An overview. *Medical Science Monitor*, 22, 2501–2512. <https://doi.org/10.12659/MSM.899852>
- Cheng, L. C., Murugaiyah, V., & Chan, K. L. (2015). Flavonoids and phenylethanoid glycosides from Lippia nodiflora as promising antihyperuricemic agents and elucidation of their mechanism of action. *Journal of Ethnopharmacology*, 176, 485–493. <https://doi.org/10.1016/j.jep.2015.11.025>
- Choi, H.K., Mount, DB., Reginato, A. M. (2005). Pathogenesis of Gout. *Annals of Internal Medicine*, 143(7), 499–516.
- Choi, H. K., & Curhan, G. (2008). Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. *British Medical Journal*, 336(309), 1–9. <https://doi.org/10.1136/bmj.39449.819271.BE>
- Choi, H. K., Willett, W., & Curhan, G. (2010). Fructose-rich beverages and risk of gout in women. *JAMA - Journal of the American Medical Association*, 304(20), 2270–2278. <https://doi.org/10.1001/jama.2010.1638>
- Choi, H., Kim, H. C., Song, B. M., Park, J. H., Lee, J. M., Yoon, D. L., Yoon, Y. M., Rhee, Y., Youm, Y., & Kim, C. O. (2016).

- Serum uric acid concentration and metabolic syndrome among elderly Koreans: The Korean Urban Rural Elderly (KURE) study. *Archives of Gerontology and Geriatrics*, 64, 51–58. <https://doi.org/10.1016/j.archger.2016.01.005>
- Choi, Y. J., Yoon, Y., Lee, K. Y., Hien, T. T., Kang, K. W., Kim, K. C., Lee, J., Lee, M. Y., Lee, S. M., Kang, D. H., & Lee, B. H. (2014). Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. *FASEB Journal*, 28(7), 3197–3204. <https://doi.org/10.1096/fj.13-247148>
- De Souza, M. R., De Paula, C. A., Pereira De Resende, M. L., Grabe-Guimarães, A., De Souza Filho, J. D., & Saúde-Guimarães, D. A. (2012). Pharmacological basis for use of *Lychnophora trichocarpa* in gouty arthritis: Anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents. *Journal of Ethnopharmacology*, 142(3), 845–850. <https://doi.org/10.1016/j.jep.2012.06.012>
- Desideri, G., Castaldo, G., Lombardi, A., Mussap, M., Testa, A., Pontremoli, R., Punzi, L., & Borghi, C. (2014). Is it time to revise the normal range of serum uric acid levels? *European Review for Medical and Pharmacological Sciences*, 18(9), 1295–1306.
- Dolati, K., Rakhshandeh, H., Golestani, M., Forouzanfar, F., Sadeghnia, R., & Sadeghnia, H. (2018). Inhibitory effects of apium graveolens on xanthine oxidase activity and serum Uric acid levels in hyperuricemic mice. *Preventive Nutrition and Food Science*, 23(2), 127–133. <https://doi.org/10.3746/pnf.2018.23.2.127>
- Dong, H., Xu, Y., Zhang, X., & Tian, S. (2017). Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes. *Scientific Reports*, 7(1), 1–13. <https://doi.org/10.1038/s41598-017-09455-z>
- Edwards, N. L. (2009). The role of hyperuricemia in vascular disorders. *Current Opinion in Rheumatology*, 21(2), 132–137. <https://doi.org/10.1097/BOR.0b013e3283257b96>
- Ekalu, A. & H. D. (2020). Flavonoids : isolation , characterization , and health benefits. *Journal of Basic and Applied Sciences*, 9(45). <https://doi.org/https://doi.org/10.1186/s43088-020-00065-9>
- Förstermann, U., Xia, N., & Li, H. (2017). Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. *Circulation Research*, 120(4), 713–735. <https://doi.org/10.1161/CIRCRESAHA.116.309326>
- Gómez, M., Vila, J., Elosua, R., Molina, L., Bruguera, J., Sala, J., Masià, R., Covas, M. I., Marrugat, J., & Fitó, M. (2014). Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population. *Atherosclerosis*, 232(1), 134–140. <https://doi.org/10.1016/j.atherosclerosis.2013.10.026>
- Grabowski, B., Khosravan, R., Wu, J. T., Vernillet, L., & Lademacher, C. (2010). Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. *British Journal of Clinical Pharmacology*, 70(1), 57–64. <https://doi.org/10.1111/j.1365-2125.2010.03667.x>
- Grundy, S. M. (2007). Metabolic syndrome: A multiplex cardiovascular risk factor. *Journal of Clinical Endocrinology and Metabolism*, 92(2), 399–404. <https://doi.org/10.1210/jc.2006-0513>
- Gulab, K. & R. K. (2016). Serum uric acid level and obesity: An association. *International Journal Health Sciences*, 4(1), 52.
- Gustafsson, D., & Unwin, R. (2013). The

- pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. *BMC Nephrology*, 14(1), 1–9. <https://doi.org/10.1186/1471-2369-14-164>
- Haidari, F., Keshavarz, S. A., Shahi, M. M., Mahboob, S. A., & Rashidi, M. R. (2011). Effects of parsley (*Petroselinum crispum*) and its flavonol constituents, kaempferol and quercetin, on serum uric acid levels, biomarkers of oxidative stress and liver xanthine oxidoreductase activity in oxonate-induced hyperuricemic rats. *Iranian Journal of Pharmaceutical Research*, 10(4), 811–819. <https://doi.org/10.22037/ijpr.2011.1016>
- Hak, A. E., Curhan, G. C., Grodstein, F., & Choi, H. K. (2010). Menopause, postmenopausal hormone use and risk of incident gout. *Annals of the Rheumatic Diseases*, 69(7), 1305–1309. <https://doi.org/10.1136/ard.2009.109884>
- Han, S., Wei, R., Han, D., Zhu, J., Luo, W., Ao, W., & Zhong, G. (2020). Hypouricemic Effects of Extracts from *Urtica hyperborea* Jacq. ex Wedd. In Hyperuricemia Mice through XOD, URAT1, and OAT1. *BioMed Research International*, 2020. <https://doi.org/10.1155/2020/2968135>
- Harwoko, H., & Warsinah, W. (2020). Phytochemical analysis and evaluation of purified extract of *Tinospora crispa* stem for in vivo antihyperuricemic effect. *Journal of Reports in Pharmaceutical Sciences*, 9(1), 46–51. https://doi.org/10.4103/jrptps.JRPTPS_4_5_19
- Huang, J., Wang, S., Zhu, M., Chen, J., & Zhu, X. (2011). Effects of genistein, apigenin, quercetin, rutin and astilbin on serum uric acid levels and xanthine oxidase activities in normal and hyperuricemic mice. *Food and Chemical Toxicology*, 49(9), 1943–1947. <https://doi.org/10.1016/j.fct.2011.04.029>
- Huo, L. N., Wang, W., Zhang, C. Y., Shi, H. B., Liu, Y., Liu, X. H., Guo, B. H., Zhao, D. M., & Gao, H. (2015). Bioassay-guided isolation and identification of xanthine oxidase inhibitory constituents from the leaves of *perilla frutescens*. *Molecules*, 20(10), 17848–17859. <https://doi.org/10.3390/molecules201017848>
- Ichida, K., Matsuo, H., Takada, T., Nakayama, A., Murakami, K., Shimizu, T., Yamanashi, Y., Kasuga, H., Nakashima, H., Nakamura, T., Takada, Y., Kawamura, Y., Inoue, H., Okada, C., Utsumi, Y., Ikebuchi, Y., Ito, K., Nakamura, M., Shinohara, Y., ... Suzuki, H. (2012). Decreased extra-renal urate excretion is a common cause of hyperuricemia. *Nature Communications*, 3, 4–6. <https://doi.org/10.1038/ncomms1756>
- Jang, I., Hyun, S., Shin, J., Lee, Y., Ji, J., & Lee, J. S. (2014). Characterization of an anti-gout xanthine oxidase inhibitor from *Pleurotus ostreatus*. *Mycobiology*, 42(3), 296–300. <https://doi.org/10.5941/MYCO.2014.42.3.296>
- Jang, I. T., Hyun, S. H., Shin, J. W., Lee, Y. H., Ji, J. H., & Lee, J. S. (2014). Characterization of an anti-gout xanthine oxidase inhibitor from *Pleurotus ostreatus*. *Mycobiology*, 42(3), 296–300. <https://doi.org/10.5941/MYCO.2014.42.3.296>
- Jang, M. G., Song, H., Lee, J. Y., Ko, H. C., Hur, S., & Kim, S. J. (2019). Protective effects of *Sasa quelpaertensis* Leaf Residue Extract against Potassium Oxonate-induced Hyperuricemia in Mice. *Journal of Life Science*, 29(1), 37–44. <https://doi.org/10.5352/JLS.2019.29.1.37>
- Jiang, L. L., Gong, X., Ji, M. Y., Wang, C. C., Wang, J. H., & Li, M. H. (2020). Bioactive compounds from plant-based functional foods: A promising choice for the prevention and management of hyperuricemia. *Foods*, 9(8). <https://doi.org/10.3390/foods9080973>

- Khanna, D. et al. (2012). ACR Guidelines: 2012 American College of Rheumatology Guidelines for Management of Gout Part I: *American College of Rheumatology*, 7(10), 3842–3845. <https://doi.org/10.1002/acr.21772>
- Khosla, U. M., Zharikov, S., Finch, J. L., Nakagawa, T., Roncal, C., Mu, W., Krotova, K., Block, E. R., Prabhakar, S., & Johnson, R. J. (2005). Hyperuricemia induces endothelial dysfunction. *Kidney International*, 67(5), 1739–1742. <https://doi.org/10.1111/j.1523-1755.2005.00273.x>
- Kodama, S., Saito, K., Yachi, Y., Asumi, M., Sugawara, A., Totsuka, K., Saito, A., & Sone, H. (2009). Association between serum uric acid and development of type 2 diabetes. *Diabetes Care*, 32(9), 1737–1742. <https://doi.org/10.2337/dc09-0288>
- Kuo, C. F., Grainge, M. J., Zhang, W., & Doherty, M. (2015). Global epidemiology of gout: Prevalence, incidence and risk factors. *Nature Reviews Rheumatology*, 11(11), 649–662. <https://doi.org/10.1038/nrrheum.2015.91>
- Kuo, C. Y., Kao, E. S., Chan, K. C., Lee, H. J., Huang, T. F., & Wang, C. J. (2012). Hibiscus sabdariffa L. extracts reduce serum uric acid levels in oxonate-induced rats. *Journal of Functional Foods*, 4(1), 375–381. <https://doi.org/10.1016/j.jff.2012.01.007>
- Li, Z., Sheng, Y., Liu, C., Li, K., Huang, X., Huang, J., & Xu, K. (2016). Nox4 has a crucial role in uric acid-induced oxidative stress and apoptosis in renal tubular cells. *Molecular Medicine Reports*, 13(5), 4343–4348. <https://doi.org/10.3892/mmr.2016.5083>
- Lin, Y., Liu, P. G., Liang, W. Q., Hu, Y. J., Xu, P., Zhou, J., Pu, J. B., & Zhang, H. J. (2018). Luteolin-4'-O-glucoside and its aglycone, two major flavones of *Gnaphalium affine* D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models. *Phytomedicine*, 41, 54–61.
- Liu, Hong, Zhang, X. M., Wang, Y. L., & Liu, B. C. (2014). Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. *Journal of Nephrology*, 27(6), 653–658. <https://doi.org/10.1007/s40620-014-0082-z>
- Liu, Huifang, Xiong, J., He, T., Xiao, T., Li, Y., Yu, Y., Huang, Y., Xu, X., Huang, Y., Zhang, J., Zhang, B., & Zhao, J. (2017). High Uric Acid-Induced Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells via the TLR4/NF-κB Signaling Pathway. *American Journal of Nephrology*, 46(4), 333–342. <https://doi.org/10.1159/000481668>
- Maheswari, U., Sridevi Sangeetha, K. S., Umamaheswari, S., Uma, C., Reddy, M., & Kalkura, S. N. (2016). Flavonoids Therapeutic Potential of Natural Pharmacological Agents. *International Journal of Pharmaceutical Sciences and Research*, 7(10), 3924. [https://doi.org/10.13040/IJPSR.0975-8232.7\(10\).3924-30](https://doi.org/10.13040/IJPSR.0975-8232.7(10).3924-30)
- Merriman, T. R. (2015). An update on the genetic architecture of hyperuricemia and gout. *Arthritis Research and Therapy*, 17(1), 1–13. <https://doi.org/10.1186/s13075-015-0609-2>
- Mohamed Isa, S. S. P., Ablat, A., & Mohamad, J. (2018). The antioxidant and xanthine oxidase inhibitory activity of plumeria rubra flowers. *Molecules*, 23(2). <https://doi.org/10.3390/molecules23020400>
- Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016). Flavonoids: An overview. *Journal of Nutritional Science*, 5. <https://doi.org/10.1017/jns.2016.41>
- Park, J.-E., Yeom, Z., Park, K.-T., Han, E. H., Yu, H. J., Kang, H. S., & Lim, Y.-H. (2018). Hypouricemic Effect of Ethanol Extract of *Aster glehni* Leaves in Potassium Oxonate-Induced

- Hyperuricemic Rats . *Clinical Nutrition Research*, 7(2), 126. <https://doi.org/10.7762/cnr.2018.7.2.126>
- Pérez-Cano, F. J., & Castell, M. (2016). Flavonoids, inflammation and immune system. *Nutrients*, 8(10), 8–11. <https://doi.org/10.3390/nu8100659>
- Qiu, L., Cheng, X. Q., Wu, J., Liu, J. T., Xu, T., Ding, H. T., Liu, Y. H., Ge, Z. M., Wang, Y. J., Han, H. J., Liu, J., & Zhu, G. J. (2013). Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. *BMC Public Health*, 13(1). <https://doi.org/10.1186/1471-2458-13-664>
- Rahmi, E. P., Kumolosasi, E., Jalil, J., Husain, K., Buang, F., Amirul, A. F., & Jamal, J. A. (2020). Anti-hyperuricemic and Anti-inflammatory Effects of Marantodes pumilum as Potential Treatment for Gout. *Frontiers in Pharmacology*, 11(March), 1–16. <https://doi.org/10.3389/fphar.2020.00289>
- Raja, S., Kumar, A., Aahooja, R. Das, Thakuria, U., Ochani, S., & Shaukat, F. (2019). Frequency of Hyperuricemia and its Risk Factors in the Adult Population. *Cureus*, 11(3). <https://doi.org/10.7759/cureus.4198>
- Rho, Y. H., Zhu, Y., & Choi, H. K. (2011). The Epidemiology of Uric Acid and Fructose. *Seminars in Nephrology*, 31(5), 410–419. <https://doi.org/10.1016/j.semnephrol.2011.08.004>
- Robinson, M. M., & Zhang, X. (2011). the World Medicines Situation 2011 Traditional Medicines : Global Situation , Issues and Challenges. *World Health Organization*, 3rd Edition, 1–14.
- Romano, B., Pagano, E., Montanaro, V., Fortunato, A. L., Milic, N., & Borrelli, F. (2013). Novel insights into the pharmacology of flavonoids. *Phytotherapy Research*, 27(11), 1588–1596. <https://doi.org/10.1002/ptr.5023>
- Romi, M. M., Arfian, N., Tranggono, U., Setyaningsih, W. A. W., & Sari, D. C. R. (2017). Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. *BMC Nephrology*, 18(1), 1–8. <https://doi.org/10.1186/s12882-017-0736-x>
- Sautin, Y. Y., Nakagawa, T., Zharikov, S., & Johnson, R. J. (2007). Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. *American Journal of Physiology - Cell Physiology*, 293(2), 584–596. <https://doi.org/10.1152/ajpcell.00600.2006>
- Shah, P., & Shah, G. (2015). Uricosuric activity of Tinospora cordifolia. *Bangladesh Journal of Pharmacology*, 10(4), 884–890. <https://doi.org/10.3329/bjp.v10i4.25160>
- Shi, Y. W., Wang, C. P., Wang, X., Zhang, Y. L., Liu, L., Wang, R. W., Ye, J. F., Hu, L. S., & Kong, L. D. (2012). Uricosuric and nephroprotective properties of Ramulus Mori ethanol extract in hyperuricemic mice. *Journal of Ethnopharmacology*, 143(3), 896–904. <https://doi.org/10.1016/j.jep.2012.08.023>
- Shi, Y., & Williamson, G. (2016). Quercetin lowers plasma uric acid in pre-hyperuricaemic males: A randomised, double-blinded, placebo-controlled, cross-over trial. *British Journal of Nutrition*, 115(5), 800–806. <https://doi.org/10.1017/S0007114515005310>
- Shih, M. H., Lazo, M., Liu, S. H., Bonekamp, S., Hernaez, R., & Clark, J. M. (2015). Association between serum uric acid and nonalcoholic fatty liver disease in the US population. *Journal of the Formosan Medical Association*, 114(4), 314–320. <https://doi.org/10.1016/j.jfma.2012.11.014>
- Siciliano, T., De Tommasi, N., Morelli, I., & Braca, A. (2004). Study of flavonoids of *Sechium edule* (Jacq) Swartz (Cucurbitaceae) different edible organs by

- liquid chromatography photodiode array mass spectrometry. *Journal of Agricultural and Food Chemistry*, *52*(21), 6510–6515.
<https://doi.org/10.1021/jf040214q>
- Skoczyńska, M., Chowaniec, M., Szymczak, A., Langner-Hetmańczuk, A., Maciążek-Chyra, B., & Wiland, P. (2020). Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) Pathophysiology of hyperuricemia and its clinical significance—a narrative review. *Reumatologia*, *58*, 312–323.
- Spanou, C., Veskoukis, A., Kerasioti, T., Kontou, M., Angelis, A., Aligiannis, N., Skaltsounis, A., & Kouretas, D. (2012). Flavonoid glycosides isolated from unique legume plant extracts as novel inhibitors of xanthine oxidase. *PLoS ONE*, *7*(3).
<https://doi.org/10.1371/journal.pone.0032214>
- Storhaug, H. M., Norvik, J. V., Toft, I., Eriksen, B. O., Løchen, M. L., Zykova, S., Solbu, M., White, S., Chadban, S., & Jenssen, T. (2013). Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: A gender specific analysis from The Tromsø Study. *BMC Cardiovascular Disorders*, *13*.
<https://doi.org/10.1186/1471-2261-13-115>
- Su, J., Wei, Y., Liu, M., Liu, T., Li, J., Ji, Y., & Liang, J. (2014). Anti-hyperuricemic and nephroprotective effects of *Rhizoma Dioscoreae septemlobae* extracts and its main component dioscin via regulation of mOAT1, mURAT1 and mOCT2 in hypertensive mice. *Archives of Pharmacological Research*, *37*(10), 1336–1344.
<https://doi.org/10.1007/s12272-014-0413-6>
- Sui, X., Church, T. S., Meriwether, R. A., Lobelo, F., & Blair, S. N. (2008). Uric acid and the development of metabolic syndrome in women and men. *Metabolism: Clinical and Experimental*, *57*(6), 845–852.
<https://doi.org/10.1016/j.metabol.2008.01.030>
- Tanaka, K., Ogata, S., Tanaka, H., Omura, K., Honda, C., & Hayakawa, K. (2015). The relationship between body mass index and uric acid: a study on Japanese adult twins. *Environmental Health and Preventive Medicine*, *20*(5), 347–353.
<https://doi.org/10.1007/s12199-015-0473-3>
- Ting, K., Gill, T. K., Keen, H., Tucker, G. R., & Hill, C. L. (2016). Prevalence and associations of gout and hyperuricaemia: Results from an Australian population-based study. *Internal Medicine Journal*, *46*(5), 566–573.
<https://doi.org/10.1111/imj.13006>
- Tremblé, J., & Šmejkal, K. (2016). Flavonoids as Potent Scavengers of Hydroxyl Radicals. *Comprehensive Reviews in Food Science and Food Safety*, *15*(4), 720–738.
<https://doi.org/10.1111/1541-4337.12204>
- Trifirò, G., Morabito, P., Cavagna, L., Ferrajolo, C., Pecchioli, S., Simonetti, M., Bianchini, E., Medea, G., Cricelli, C., Caputi, A. P., & Mazzaglia, G. (2013). Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: A nationwide population-based study. *Annals of the Rheumatic Diseases*, *72*(5), 694–700.
<https://doi.org/10.1136/annrheumdis-2011-201254>
- Tsushima, Y., Nishizawa, H., Tochino, Y., Nakatsuji, H., Sekimoto, R., Nagao, H., Shirakura, T., Kato, K., Imaizumi, K., Takahashi, H., Tamura, M., Maeda, N., Funahashi, T., & Shimomura, I. (2013). Uric acid secretion from adipose tissue and its increase in obesity. *Journal of Biological Chemistry*, *288*(38), 27138–27149.
<https://doi.org/10.1074/jbc.M113.485094>
- Van Hoorn, D. E. C., Nijveldt, R. J., Van Leeuwen, P. A. M., Hofman, Z., M'Rabet, L., De Bont, D. B. A., & Van Norren, K. (2002). Accurate prediction of xanthine

- oxidase inhibition based on the structure of flavonoids. *European Journal of Pharmacology*, 451(2), 111–118. [https://doi.org/10.1016/S0014-2999\(02\)02192-1](https://doi.org/10.1016/S0014-2999(02)02192-1)
- Villegas, R., Xiang, Y. B., Elasy, T., Xu, W. H., Cai, H., Cai, Q., Linton, M. F., Fazio, S., Zheng, W., & Shu, X. O. (2012). Purine-rich foods, protein intake, and the prevalence of hyperuricemia: The Shanghai Men's Health Study. *Nutrition, Metabolism and Cardiovascular Diseases*, 22(5), 409–416. <https://doi.org/10.1016/j.numecd.2010.07.012>
- Wang, Honggang, Wang, L., Xie, R., Dai, W., Gao, C., Shen, P., Huang, X., Zhang, F., Yang, X., & Ji, G. (2014). Association of serum uric acid with body mass index: A cross-sectional study from Jiangsu province, China. *Iranian Journal of Public Health*, 43(11), 1503–1509.
- Wang, Hongsha, Zhang, H., Sun, L., & Guo, W. (2018). Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. *American Journal of Translational Research*, 10(9), 2749–2763.
- Wang, M., Jiang, X., Wu, W., & Zhang, D. (2013). A meta-analysis of alcohol consumption and the risk of gout. *Clinical Rheumatology*, 32(11), 1641–1648. <https://doi.org/10.1007/s10067-013-2319-y>
- Wang, S., Fang, Y., Yu, X., Guo, L., Zhang, X., & Xia, D. (2019). The flavonoid-rich fraction from rhizomes of *Smilax glabra* Roxb. ameliorates renal oxidative stress and inflammation in uric acid nephropathy rats through promoting uric acid excretion. *Biomedicine and Pharmacotherapy*, 111(December 2018), 162–168. <https://doi.org/10.1016/j.biopha.2018.12.050>
- Wu, J., Lei, G., Wang, X., Tang, Y., Cheng, H., Jian, G., Wu, X., & Wang, N. (2017). Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. *Oncotarget*, 8(46), 80688–80699. <https://doi.org/10.18632/oncotarget.21079>
- Yan, J., Zhang, G., Hu, Y., & Ma, Y. (2013). Effect of luteolin on xanthine oxidase: inhibition kinetics and interaction mechanism merging with docking simulation. *Food Chemistry*, 141(4), 3766–3773. <https://doi.org/10.1016/j.foodchem.2013.06.092>
- Yu, K. H., See, L. C., Huang, Y. C., Yang, C. H., & Sun, J. H. (2008). Dietary Factors Associated with Hyperuricemia in Adults. *Seminars in Arthritis and Rheumatism*, 37(4), 243–250. <https://doi.org/10.1016/j.semarthrit.2007.04.007>
- Yuan, H., Yu, C., Li, X., Sun, L., Zhu, X., Zhao, C., Zhang, Z., & Yang, Z. (2015). Serum uric acid levels and risk of metabolic syndrome: A dose-response meta-analysis of prospective studies. *Journal of Clinical Endocrinology and Metabolism*, 100(11), 4198–4207. <https://doi.org/10.1210/jc.2015-2527>
- Yuan, M., Liu, Y., Xiao, A., Leng, J., Liao, L., Ma, L., & Liu, L. (2019). The interaction of dietary flavonoids with xanthine oxidase: In vitro: Molecular property-binding affinity relationship aspects. *RSC Advances*, 9(19), 10781–10788. <https://doi.org/10.1039/c8ra09926j>
- Yuk, H. J., Lee, Y. S., Ryu, H. W., Kim, S. H., & Kim, D. S. (2018). Effects of toona sinensis leaf extract and its chemical constituents on xanthine oxidase activity and serum uric acid levels in potassium oxonate-induced hyperuricemic rats. *Molecules*, 23(12), 54. <https://doi.org/10.3390/molecules23123254>
- Zalawadiya, S. K., Veeranna, V., Mallikethi-Reddy, S., Bavishi, C., Lunagarria, A., Kottam, A., & Afonso, L. (2015). Uric acid and cardiovascular disease risk

- reclassification: Findings from NHANES III. *European Journal of Preventive Cardiology*, 22(4), 513–518. <https://doi.org/10.1177/2047487313519346>
- Zhu, Y., Pandya, B., Choi, H. K. (2011). Prevalence of Gout and Hyperuricemia in the US General Population The National Health and Nutrition Examination Survey 2007 – 2008. *Arthritis and Rheumatism*, 63(10), 3136–3141. <https://doi.org/10.1002/art.30520>
- Zhu, J. X., Wang, Y., Kong, L. D., Yang, C., & Zhang, X. (2004). Effects of *Biota orientalis* extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. *Journal of Ethnopharmacology*, 93(1), 133–140. <https://doi.org/10.1016/j.jep.2004.03.037>

Cite this article as: Putri, D. P., & Putra, K. W. R. (2024). The Effect of Flavonoids in Plants as Antihyperuricemia: A Literature Review. *Nurse and Health: Jurnal Keperawatan*, 13 (1), 109-126. <https://doi.org/10.36720/nhjk.v13i1.635>